Txp Pharma Gmbh

Gilead Sciences, Inc.

Lica Pharmaceuticals A/s

Synact Pharma Aps

Epitherapeutics Aps

Thomas Boesen

Marc A Labelle

Farman Ullah

Mukund Mehrotra

Qasim Khan

Ying Yang

Simon Feldbæk Nielsen

Bent Højgaard

Ramkrishna Reddy Vakiti

Neerja Saraswat

Mogens Larsen

Utpal Sharma

Hasse Kromann

Cyril Cook

Dastagiri Dudekula

Thomas Engelbrecht Nordkild Jonassen

Rui Zhang

Kristian Schønning

Mette Bjerg Nielsen

Hayley Ann Reece

Alice Jane Turner

Ross Mclellan

Natalie Louise Kelk

Marc Labelle

The present disclosure relates to crystalline forms of N-{3-[1-(2-nitrophenyl)-1H-pyrrol-2-yl]-allylidene}-aminoguanidinium salts having high solubility. The disclosure also relates to use of said crystalline forms in medicine.

Polymorphs of phenyl pyrrole aminoguandium salts

The present invention relates to peptide analogues comprising one or more branched amino acid probes and a peptide, native or variants thereof.

Peptide analogues with branched amino acid probe(s)

The present application discloses compounds capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer. The present application also discloses pharmaceutical compositions comprising said compounds and the use of such compounds as a medicament. The compounds take the form 

Inhibitors of histone demethylases

The present invention provides peptide analogs of &#x3b1;-MSH and &#x3b3;-MSH, comprising the amino acid sequence of human &#x3b1;-MSH or &#x3b3;-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.

Alpha- and gamma-MSH analogues

The present invention relates to peptide analogs comprising one or more branched amino acid probes and a peptide, native or variants thereof.

The present application relates to compounds being of Formula (I), (II), (III), (IV), (V), (VI), (IIIa), (IIIb), (IIIc), (IIId), (IIIe), (IIIf), and (IIIg). Compounds of Formula (I) have the structure: wherein Q, R, R, R, M, A and Y are as defined herein. The compounds of the application can modulate the activity of histone demethylases (HDMEs), and can be useful for the prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, e.g., cancer.

Compounds and methods for inhibiting histone demethylases

Compounds of the form In which Q is selected from &#x2014;CH&#x2550;NR, &#x2014;W, &#x2014;CHNHR, &#x2014;CH&#x2550;O and &#x2014;CH(OR)capable of modulating the activity of histone demethylases (HDMEs), which are useful for prevention and/or treatment of diseases in which genomic dysregulation is involved in the pathogenesis, such as e.g. cancer and formulations and methods of use of such compounds.

The present invention provides peptide analogues of &#x3b1;-MSH and &#x3b3;-MSH, comprising the amino acid sequence of human &#x3b1;-MSH or &#x3b3;-MSH, or variants thereof, and having a branched amino acid probe in the N-terminal part of the peptide.

Alpha-and gamma-MSH analogues

The invention provides novel diamino-functionalized chalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also disclosed. The invention further relates to a method for detecting inhibitory effects against e.g., bacteria, parasites, fungi, and helminths. The chalcones of the invention carry amino substituents and exhibit enhanced biological effects combined with improved metabolic and physicochemical properties, making the compounds useful as drug substances, in particular as antiparasitic and bacteriostatic agents.

Diamino-functional chalcones

The invention provides novel alkoxyaminochalcone derivatives and analogues thereof. Use of the compounds, or compositions comprising them, as pharmaceutically active agents, in particular against bacterial and parasitic infections, is also disclosed. The invention further relates to a method for detecting inhibitory effects against e.g., bacteria, parasites, fungi, and helminths. The chalcones of the invention carry amino substituents and exhibit enhanced biological effects combined with improved metabolic and physicochemical properties, making the compounds useful as drug substances, in particular as antiparasitic, bacteriostatic, and bacteriocidal agents.

Growing community of inventors

Copenhagen, Denmark

Thomas Boesen